Form 8-K - Current report:
SEC Accession No. 0001193125-25-317577
Filing Date
2025-12-12
Accepted
2025-12-12 16:15:25
Documents
15
Period of Report
2025-12-10
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d68980d8k.htm   iXBRL 8-K 25969
2 EX-1.1 d68980dex11.htm EX-1.1 211324
3 EX-5.1 d68980dex51.htm EX-5.1 8929
7 GRAPHIC g68980dsp00.jpg GRAPHIC 3638
  Complete submission text file 0001193125-25-317577.txt   421546

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA imvt-20251210.xsd EX-101.SCH 2846
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE imvt-20251210_lab.xml EX-101.LAB 17234
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE imvt-20251210_pre.xml EX-101.PRE 10809
17 EXTRACTED XBRL INSTANCE DOCUMENT d68980d8k_htm.xml XML 3496
Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-38906 | Film No.: 251568280
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)